Thirty years of progress in the management of low- grade gliomas

This paper reviews 30 years of developments in the area of low-grade gliomas. This includes the changes in diagnostics with the incorporation of 1p/19q and IDH mutations in the diagnostic classifier, the improved surgical techniques, improved delivery of radiotherapy and chemotherapy. More recently, the better understanding of the altered cellular processes has lead to the development of novel drugs that may alter completely alter the management of patients early in the course of their disease.(c) 2023 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Automated summary

This paper reviews the 30-year development of low-grade gliomas, including changes in diagnostics with the incorporation of 1p/19q and IDH mutations, improved surgical techniques, and improved delivery of radiotherapy and chemotherapy. Recently, the better understanding of altered cellular processes has led to the development of novel drugs that may completely alter the management of patients early in their disease.